Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment

• DOI: 10.1016/j.ctarc.2024.100836
• Publication Date: 2024-07-30T16:35:20Z
• Authors: Saki Tanaka; Motohiro Tamiya; Satoshi Nishiuma; Sayaka Nakamura; Keisuke Nozaki; Naoko Watanabe; Chisae Itoh; Yukio Kadokawa; Kenji Takeda; Kozo Takahashi; Akito Miyazaki; Takahisa Kawamura; Kei Kunimasa; Takako Inoue; Kazumi Nishino; Mari Takagi
• Keywords: Osimertinib; Body surface area

The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. dosage of fixed at 80 mg/day regardless body surface area (BSA), however some patients withdraw or reduce the due to adverse events (AEs). We performed a retrospective cohort study 98 with EGFR mutation-positive non-small cell (NSCLC), who received mg as initial treatment. investigated impact BSA on efficacy and safety osimertinib. cut-off value was estimated using receiver operating characteristics curve, determined be 1.5 m2. There were 44 in < group 54 ≥ group. no significant difference incidence AEs (hematologic toxicity ≥grade 3 higher, non-hematologic 3) between two groups. However, dose reduction significantly higher compared (16 vs 5 patients, p = 0.003). main reasons fatigue, anorexia, diarrhea, liver disfunction. Median progression-free survival (PFS) not different (16.9 months 18.1 group, 0.869). Differences affected optimal PFS by BSA. Therefore, when an EGFR-mutant NSCLC, control should considered, especially BSA<1.5